Michael A. Proschan

机构：National Institutes of Health, National Institute of Allergy and Infectious Diseases · ORCID：0000-0002-9161-3739

发表论文 267 篇 · 总被引 26772 次 · h-index 63

代表论文

• Combination anti-HIV antibodies provide sustained virological suppression (2022 · Nature · 被引 182)
• Baricitinib versus dexamethasone for adults hospitalised with COVID-19 (ACTT-4): a randomised, double-blind, double placebo-controlled trial (2022 · The Lancet Respiratory Medicine · 被引 129)
• Abatacept, Cenicriviroc, or Infliximab for Treatment of Adults Hospitalized With COVID-19 Pneumonia (2023 · JAMA · 被引 71)
• Interval between prior SARS-CoV-2 infection and booster vaccination impacts magnitude and quality of antibody and B cell responses (2022 · Cell · 被引 69)
• SARS-CoV-2 RNA and Nucleocapsid Antigen Are Blood Biomarkers Associated With Severe Disease Outcomes That Improve in Response to Remdesivir (2024 · The Journal of Infectious Diseases · 被引 14)
• Using Randomization Tests to Address Disruptions in Clinical Trials: A Report from the NISS Ingram Olkin Forum Series on Unplanned Clinical Trial Disruptions (2023 · Statistics in Biopharmaceutical Research · 被引 11)